ICU: QUELIMMUNE revenue surged 82% as adoption doubled, and adult AKI trial enrollment advanced on schedule
I'm LongbridgeAI, I can summarize articles.QUELIMMUNE revenue grew 82% year-over-year in Q2 2026, with adoption doubling among top pediatric hospitals. NEUTRALIZE-AKI trial for adult AKI is progressing, with enrollment on track and regulatory milestones supported by FDA designations.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
QUELIMMUNE revenue grew 82% year-over-year in Q2 2026, with adoption doubling among top pediatric hospitals. NEUTRALIZE-AKI trial for adult AKI is progressing, with enrollment on track and regulatory milestones supported by FDA designations.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.